Jeffrey J. Zuravleff
University of Pittsburgh
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jeffrey J. Zuravleff.
The American Journal of Medicine | 1989
Megan Hilf; Victor L. Yu; Joann Sharp; Jeffrey J. Zuravleff; Joyce Korvick; Robert R. Muder
PURPOSE AND PATIENTS AND METHODS We performed a prospective clinical study of 200 consecutive patients with Pseudomonas aeruginosa bacteremias to analyze in vitro susceptibility and synergistic testing of antibiotics the patients received and clinical parameters to assess their relationship to survival. RESULTS No significant correlation between in vitro susceptibility testing (minimal inhibitory concentrations/minimal bactericidal concentrations) and outcome could be demonstrated. Similarly, improved outcome could not be demonstrated for patients receiving antibiotic combinations that were synergistic in vitro (either time-kill or checker-board) versus those combinations that were not. There was also no correlation between results obtained by time-kill curve and checkerboard synergistic testing, i.e., combinations found to be synergistic by one method were not necessarily synergistic by the other method. Clinical parameters associated with improved survival were a urinary portal of entry and absence of neutropenia. Conversely, survival was significantly decreased when the portal was the respiratory tract. The mortality rate between patients receiving combination therapy (27%) and monotherapy (47%) was significant (p less than 0.02); this significant relationship held true for most subgroups including malignancy, nosocomial infection, and infection site. CONCLUSION Increasing effort should be placed on ensuring timely administration of combination therapy to patients with P. aeruginosa bacteremia since the use of combination therapy was even more important in determining outcome than was underlying disease.
The New England Journal of Medicine | 1986
Victor L. Yu; Angella Goetz; Marilyn M. Wagener; Peter B. Smith; John D. Rihs; James E. Hanchett; Jeffrey J. Zuravleff
We conducted a five-year prospective controlled study of prophylaxis of Staphylococcus aureus nasal carriage and infection among patients in a hemodialysis unit. Carriers tended to have chronic colonization with a single phage type. S. aureus infections occurred significantly more frequently in carriers than in noncarriers and, in 93 percent of the infected carriers, were caused by the same phage type as that carried in the nares. Neither intravenous vancomycin nor topical bacitracin was found to be efficacious in eradicating nasal carriage. However, oral rifampin given for five days decreased S. aureus carriage over a one-month follow-up period, but within three months colonization of the nares recurred in most carriers, often with an S. aureus of the original phage type. Carriers were then randomly assigned to receive either rifampin or no prophylaxis. Rifampin was readministered at three-month intervals if culture of the anterior nares yielded S. aureus. Infections with S. aureus occurred significantly more frequently in carriers given no prophylaxis than in those given a full course of rifampin. S. aureus resistant to rifampin was isolated from the anterior nares of four patients, but these isolates were not implicated in any infections. The incidence of infection at the dialysis access site, skin, and soft tissue of patients on hemodialysis can be decreased by interventions directed at nasal carriage of S. aureus.
Annals of Internal Medicine | 1982
Victor L. Yu; Jeffrey J. Zuravleff; Elaine M. Elder; Arnold L. Brown
Excerpt The pittsburgh pneumonia agent is a newly recognized cause of pneumonia (1, 2). Although most patients have been renal transplant recipients (1-4), others have had malignant disease or rece...
Therapeutic Drug Monitoring | 1981
Warren F. Diven; Boyd D. Obermeyer; Robert L. Wolen; Victor L. Yu; James Lyon; Jeffrey J. Zuravleff
We describe a sensitive high pressure liquid chromatographic (HPLC) procedure for the analysis of the new beta-lactam antibiotic moxalactam. Conditions are described for either measurement of total drug concentration or the concentration of the individual isomers. The proteins in a 1.0 ml plasma sample are denatured with isopropyl alcohol which is then extracted into a chloroform reagent, leaving the drug in the aqueous phase. An aliquot is then injected into a mu-bondapak phenyl column. A similar extraction procedure was employed for tissue homogenates. Linear regression analysis and comparison of the HPLC assay with the microbiological assay gave a correlation coefficient of 0.97. Analysis of tissue samples indicated that significant concentrations of moxalactam were obtained at the site of infection.
The New England Journal of Medicine | 1982
Janet E. Stout; Victor L. Yu; RichardM Vickers; Jeffrey J. Zuravleff; Michele G. Best; Arnold L. Brown; Robert Yee; Robert M. Wadowsky
Clinical Infectious Diseases | 1982
Jeffrey J. Zuravleff; Victor L. Yu
Medicine | 1983
Robert R. Muder; Victor L. Yu; Jeffrey J. Zuravleff
The American review of respiratory disease | 1983
Jeffrey J. Zuravleff; Victor L. Yu; John W. Shonnard; John D. Rihs; Michele G. Best
Journal of Antimicrobial Chemotherapy | 1984
Victor L. Yu; Jeffrey J. Zuravleff; Jon Bornholm; Gordon L. Archer
The Journal of Infectious Diseases | 1983
Victor L. Yu; Jeffrey J. Zuravleff; Lora Gavlik; Margaret H. Magnussen